Antisense oligonucleotides of the human chk1 gene and uses thereof
CA 2402041 A1 · Owner: Abbott Laboratories · Inventors: Rockow-Magnone, Shayna K.; Giranda, Vincent L.; Luo, Yan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The subject invention relates to antisense oligonucleotides of the human Chk1 gene and to uses thereof. The human ChK1 gene is a major G2/M checkpoint gene that is activated in response to DNA damage. In particular the gene , transduces the inhibitory signal from DNA damage sensors to the basic cell cycle machinery. Thus, antisense oligonucleotides to the human Chk1 gene may be used, for example, to inhibit the gene thereby preventing G2 arrest induced by DNA damaging agents. Such antisense oligonucleotides should also further sensitize tumor cells thereby making them more sensitive to therapy than normal cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 2, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 2, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 2, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.